Neurologix to showcase novel gene transfer approach to Parkinson’s disease

Download PDF Copy

Editorial Checklist

Reviewed

Sep 15 2009

Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that the company will showcase its novel gene transfer approach to Parkinson’s disease and other serious brain and central nervous system diseases at the BioPharm America partnering conference being held in San Francisco, CA on September 17 – 18. John Mordock, Neurologix President and Chief Executive Officer, will discuss the company’s technology, ongoing Phase 2 trial in advanced Parkinson’s disease and other development programs from 4:15 – 4:30 on Thursday September 17 in Salon 14 at the Marriott San Francisco.

Source:

http://www.neurologix.net/

Posted in: Medical Science News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Blood test for tumor DNA may predict melanoma recurrence

Blood test for tumor DNA may predict melanoma recurrence

Rare TYROBP gene variant found in Finns linked to increased Alzheimer's risk

Rare TYROBP gene variant found in Finns linked to increased Alzheimer's risk

Reprogramming the colon could be a therapeutic strategy for short bowel syndrome

Reprogramming the colon could be a therapeutic strategy for short bowel syndrome

New study connects parasitic disease to genetic changes in the cervical lining

New study connects parasitic disease to genetic changes in the cervical lining

New study sheds light on 3D gene hubs driving brain cancer

New study sheds light on 3D gene hubs driving brain cancer

Machine learning unlocks millions of safer CRISPR enzymes for gene editing

Machine learning unlocks millions of safer CRISPR enzymes for gene editing

Cell-by-cell analysis reveals brain changes in Tourette syndrome

Cell-by-cell analysis reveals brain changes in Tourette syndrome

Gene-edited immune cells show promise against advanced GI cancers

Gene-edited immune cells show promise against advanced GI cancers

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Gene therapy offers hope for children born with metachromatic leukodystrophy